Naoxintong Capsule for Secondary Prevention of Ischemic Stroke: A Multicenter, Randomized, and Placebo-Controlled Trial

Yu, Xiaofei; Zhu, Xuying; Yuan, Can-Xing; Wu, Danhong; Zhao, Yuwu; Yang, Jiajun; Wang, Changde; Wu, Wei-wen; Liu, Xue-Yuan; Liu, Zhenguo; Nie, Zhiyu; Deng, Bo; Bao, Huan; Wang, Chunyan; Zhang, Hongzhi; Zhang, Jing-si; Huang, Jihan; Gong, Fan; Wang, Mingzhe; Guo, Yong-Mei; Sun, Yan; Cai, Dingfang

doi:10.1007/s11655-022-3586-8

Cited by 5 publications

(3 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For example, in a multicenter RCT, 2,200 patients with a history of ischemic stroke were randomized 1:1 to receive either Naoxintong capsule ( Salvia miltiorrhiza -based CPM) or placebo in addition to standard care. Compared with the placebo group, the recurrence rate of ischemic stroke within 2 years was significantly lower in the Naoxintong group (P = 0.008), without increasing the risk of major bleeding in high-risk patients 14 . A systematic review and meta-analysis of 15 RCTs found that Ginkgo biloba extract (GBE, Ginkgo biloba -based CPM) improves neurological function and dependency in patients with different stages of ischemic stroke compared with conventional therapy and is generally safe for clinical use.…”

Section: Discussionmentioning

confidence: 86%

Analysis of online prescription patterns in Chinese patients with sequelae of cerebral infarction: a real-world study

Tang,

Song,

Kuang

et al. 2024

Sci Rep

View full text Add to dashboard Cite

Cerebral infarction (CI) is a common cerebrovascular disease worldwide, and the burden caused by the sequelae of CI has increased significantly. However, current treatment guidelines lack standardized recommendations for pharmacotherapy of sequelae of CI. This retrospective study collected and analyzed 1.98 million prescriptions concerning sequelae of CI from patients admitted to Zhiyun Health Internet Hospital in 2022. The mean age of patients was 66.2 ± 11.4 years, and 52.40% were male. 79.73% had one or more comorbidities. For treatment, the prescriptions of 1-, 2- and ≥ 3-drug accounted for 64.55%, 23.77% and 11.68% respectively. Chinese patent medicine (CPM) prescriptions, western medicine (WM) prescriptions, and CPM and WM combined (CPM + WM) prescriptions accounted for 53.81%, 27.33%, and 18.86% respectively. In CPM prescriptions, the most frequently prescribed medications were Salvia miltiorrhiza (34.81%), Ginkgo biloba (24.96%), Panax notoginseng (20.67%), Gastrodia (7.15%) and Ligusticum Wallichii (4.90%). For WM prescriptions, the most commonly prescribed agents were anti-hypertensive (32.82%), anti-thrombotic (16.06%), vasodilator (15.70%), anti-dementia (10.88%), and lipid-lowering (9.58%) drugs. Among CPM + WM prescriptions, 72.61% had CPM/WM = 1, 21.20% had CPM/WM < 1, and 6.19% had CPM/WM > 1. This research utilized real-world data extracted from internet hospitals in China to present valuable evidence of online prescription patterns among patients experiencing sequelae of CI.

show abstract

Section: Discussionmentioning

confidence: 86%

Analysis of online prescription patterns in Chinese patients with sequelae of cerebral infarction: a real-world study

Tang,

Song,

Kuang

et al. 2024

Sci Rep

View full text Add to dashboard Cite

show abstract

“…Safflower, Astragalus, whole scorpion, Peach kernel, Dilong, salvia and frankincense are among the sixteen herbs that make up the Chinese medicinal preparation known as Brain Heart Capsule. These herbs work together to improve blood viscosity, inhibit platelet aggregation, increase the activity of fibrinogen and activate blood circulation, all of which contribute to the prevention of thrombosis [5]. In order to minimize the recurrence of IS, the effect of combination of aspirin with Cerebrocardiac capsules has been investigated in this study.…”

Section: Introductionmentioning

confidence: 99%

Efficacy of cerebroxin capsules combined with aspirin in prevention of post-ischemic stroke in patients treated with thrombolysis

Wang,

Tan

2024

Trop. J. Pharm Res

View full text Add to dashboard Cite

Purpose: To analyze the efficacy of Cerebro-Cardiac capsules combined with aspirin for secondary prevention in post-ischemic stroke patients treated with thrombolysis, and also to explore its clinical application value. Methods: 224 ischemic stroke patients in the outpatient clinic of Changsha First Hospital, China from June 2022 to December 2022 were randomly divided into treatment and control groups, with 112 patients per group. Both groups were given oral aspirin (100 mg/daily) but treatment group received cerebroxin capsules (four capsules, three times daily) in addition. The types of recurrent strokes, clinical efficacy, NIHSS score scale, modified Barthel index, levels of fibrinogen and plasma viscosity, total cholesterol and triacylglycerol were assessed and compared between the groups. Results: During the 6-month follow-up, 10 patients in treatment group and 12 patients in control group experienced dislodgment, and 202 cases completed treatment, but the difference was not statistically significant (p > 0.05). Treatment group showed a higher effective rate (92 %) compared to control group (75 %), with a statistically significant difference in clinical symptom efficacy (p < 0.05). Hemodynamic parameters were significantly better in treatment group than in control group (p < 0.05). Both groups exhibited improved total cholesterol levels, triacylglycerol levels and modified Barthel index post-treatment. Treatment group had better NIHSS scores and Barthel index than control group (p < 0.05), while their triacylglycerol levels were lower (p < 0.05). Conclusions: Cerebroxin capsules combined with aspirin improve the symptomatic effect of thrombolytic therapy in patients after ischemic stroke with high safety profile. Analysis of the effect of this combination in an increased sample size and a longer follow-up period will be required in the future.

show abstract

“…[7,8] Chinese herbal medicine is recommended by guidelines for secondary prevention of ischemic stroke, and its application in clinical practice to activate blood circulation and resolve blood stasis reduces the 2-year stroke recurrence rate in patients with ischemic stroke and does not increase the risk of bleeding in high-risk patients. [9] The combination of blood-activating herbs and western medicine can effectively improve the quality of daily life of patients, and the combination of Chinese and Western medicine has advantages in the clinical treatment of ischemic stroke. [10] Based on this, we conducted this systematic evaluation to assess the efficacy and safety of combining EDA with herbs that activate blood circulation and resolve blood stasis in the treatment of acute cerebral infarction, and to provide a basis for clinical decision making.…”

Section: Introductionmentioning

confidence: 99%

Efficacy and safety of blood-activating herbs combined with edaravone in the treatment of acute ischemic stroke: A protocol for systematic review and meta-analysis

Zhang

et al. 2022

Medicine

View full text Add to dashboard Cite

Background: Although the combination of blood-activating herbs and western drugs has shown advantages in the treatment of ischemic stroke, there is no consensus on the safety and efficacy. This study aimed to systematically evaluate the safety and efficacy of the combination of blood-activating herbs with edaravone (EDA) in the treatment of acute ischemic stroke (AIS). Methods: We will implement the search strategy in 8 English and Chinese databases: Cochrane Central Register of Controlled Trials, Web of Science, PubMed, China National Knowledge Infrastructure, China Science and Technology Journal Database, Wanfang Database, EMBASE and MEDLINE. The search included relevant clinical randomized controlled trials and quasi-randomized controlled trials that had been registered for publication by November 2022. Literature screening, data extraction and quality assessment will be performed by 2 authors. We will assess the risk of bias according to the Cochrane Handbook for Systematic Reviews of Interventions. The Grading of Recommendations Assessment, Development, and Evaluation (GRADE) method classification will be used to assess the quality of the literature. Meta-analysis was performed using RevMan V.5.4 and STATA 16 software. Results: This study will provide a comprehensive analysis of the current clinical evidence on the application of blood-activating herbs combined with EDA in the treatment of AIS. Conclusion: This study will clarify the safety and efficacy of the combination of blood-activating herbs with EDA in the treatment of AIS.

show abstract

Naoxintong Capsule for Secondary Prevention of Ischemic Stroke: A Multicenter, Randomized, and Placebo-Controlled Trial

Cited by 5 publications

References 34 publications

Analysis of online prescription patterns in Chinese patients with sequelae of cerebral infarction: a real-world study

Analysis of online prescription patterns in Chinese patients with sequelae of cerebral infarction: a real-world study

Efficacy of cerebroxin capsules combined with aspirin in prevention of post-ischemic stroke in patients treated with thrombolysis

Efficacy and safety of blood-activating herbs combined with edaravone in the treatment of acute ischemic stroke: A protocol for systematic review and meta-analysis

Contact Info

Product

Resources

About